Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Ask the Doctor Question: I am 66 years old and diagnosed with CLL three-years ago. My WBC auto was 71.3 three-months ago, but now jumped to 178.1. My doctor is telling
I’ve never really thought about putting this role to paper but come to think of it, this may be a very therapeutic exercise for me. So here goes.
Various combinations of venetoclax plus other agents such as venetoclax plus rituximab (RVe), venetoclax and obinutuzumab (GVe), or venetoclax plus rituximab plus obinutuzumab (GIVe) provide fixed duration treatment options with high rates of success.
Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL. It will also provide news, help with the acronyms and new vocabulary words, and offer simple fun quizzes. The cycle restarts and it is updated annually.
At the annual meeting of the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman, interviewed Dr. Stephan Stilgenbauer, Professor of Medicine at the Comprehensive Cancer Center at Ulm University in Germany. They discussed the latest results from the GAIA (CLL13) trial, which compared rates of measurable residual disease (MRD) with the different treatments.
Chronic Lymphocytic Leukemia (CLL) is a heterogeneous illness with a variable clinical course primarily determined by the disease’s underlying genetics, which is not the same for each affected individual. However, one gene that is highly important in predicting the natural history of CLL and response to chemoimmunotherapy is TP53, which resides on chromosome 17.
While this oral medication has dramatically improved the treatment of chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL), there is concern about the risk of heart or cardiovascular (CV) adverse effects due to off-target kinase inhibition.
Discussion of preliminary results from an ongoing phase 1 clinical trial studying the safety and efficacy of novel BCL2 inhibitor BGB-11417 alone and in combination with the next-generation BTK inhibitor zanubrutinib.
Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL. It will also provide news, help with the acronyms and
One click to our most popular content.
